Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMKUE8O)

Drug Name
RP5063 Drug Info
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Phase 2 [1]
Alzheimer disease 8A20 Phase 1 [2]
Attention deficit hyperactivity disorder 6A05.Z Phase 1 [2]
Bipolar disorder 6A60 Phase 1 [2]
Major depressive disorder 6A70.3 Phase 1 [2]
Parkinson disease 8A00.0 Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMKUE8O

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Antagonist [3]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Partial agonist [2]
5-HT 7 receptor (HTR7) TTO9X1H 5HT7R_HUMAN Partial agonist [2]
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Antagonist [3]
Dopamine D3 receptor (D3R) TT4C8EA DRD3_HUMAN Partial agonist [2]
Dopamine D4 receptor (D4R) TTE0A2F DRD4_HUMAN Partial agonist [2]
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Partial agonist [2]
Serotoninnorepinephrinedopamine reuptake (SNDR) TT8G3Z7 NOUNIPROTAC Partial agonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Histamine H1 receptor (H1R) DTT HRH1 5.972 5.7 5.816 6.002
5-HT 1A receptor (HTR1A) DTT HTR1A 4.661 5.289 3.053 3.472
5-HT 7 receptor (HTR7) DTT HTR7 1.561 1.233 0.848 1.485
5-HT 2A receptor (HTR2A) DTT HTR2A 4.84 4.904 4.652 4.129
Dopamine D2 receptor (D2R) DTT DRD2 5.345 5.634 5.789 5.901
Dopamine D4 receptor (D4R) DTT DRD4 2.138 1.766 1.322 1
Dopamine D3 receptor (D3R) DTT DRD3 1.379 2.446 1.233 1.07
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Schizophrenia
ICD Disease Classification 6A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 1A receptor (HTR1A) DTT HTR1A 1.49E-05 -0.22 -0.58
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01490086) RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Drug Development in Schizophrenia: Summary and Table. Pharmaceutical Medicine October 2014, Volume 28, Issue 5, pp 265-271